CastleVax Announces Initiation of a Phase 2 Study Evaluating Its Mucosally-delivered, Next Generation, COVID-19 Vaccine Candidate
CastleVax, a clinical-stage biotechnology company developing intranasal vaccines using its attenuated Newcastle Disease Virus (NDV)-based vaccine platform, announced today that the first participant has been dosed in a Phase 2 clinical study of CVAX-01, its intranasal, next-generation, COVID-19 vaccine candidate. The study is designed to evaluate the safety, tolerability and both systemic and mucosal immunogenicity of CVAX-01 against a U.S. Food and Drug Administration (FDA)-approved injectable mRNA-based COVID-19 vaccine (NCT07215520).
